Corinne Jenkins
Stock Analyst at Goldman Sachs
(3.35)
# 1,080
Out of 4,479 analysts
62
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $6.10 | +145.90% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $33.72 | +36.42% | 5 | May 13, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $67 → $77 | $68.54 | +12.34% | 4 | Apr 17, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $10.56 | +70.45% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $4.17 | +19.90% | 3 | Mar 15, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $12 → $13 | $18.31 | -29.00% | 6 | Feb 29, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $42 → $52 | $42.34 | +22.82% | 7 | Jan 26, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $6.74 | +92.88% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $30.00 | -6.67% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $37.27 | +39.52% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $12 → $4 | $1.12 | +257.14% | 5 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $27 → $23 | $2.79 | +724.37% | 2 | Mar 15, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Buy | $25 → $21 | $1.14 | +1,742.11% | 2 | Mar 7, 2023 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $9 → $14 | $6.72 | +108.33% | 2 | Dec 20, 2022 | |
| GRTS Gritstone bio | Downgrades: Sell | $2 | $0.57 | +249.04% | 1 | Aug 22, 2022 | |
| RDUS Radius Health | Maintains: Neutral | $9 → $8 | $14.67 | -45.47% | 2 | May 24, 2022 | |
| ATHA Athira Pharma | Initiates: Neutral | n/a | $2.52 | - | 1 | Dec 15, 2021 |
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $6.10
Upside: +145.90%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $33.72
Upside: +36.42%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Neutral
Price Target: $67 → $77
Current: $68.54
Upside: +12.34%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $10.56
Upside: +70.45%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $4.17
Upside: +19.90%
TG Therapeutics
Feb 29, 2024
Maintains: Neutral
Price Target: $12 → $13
Current: $18.31
Upside: -29.00%
Rhythm Pharmaceuticals
Jan 26, 2024
Maintains: Buy
Price Target: $42 → $52
Current: $42.34
Upside: +22.82%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $6.74
Upside: +92.88%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $30.00
Upside: -6.67%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $37.27
Upside: +39.52%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $12 → $4
Current: $1.12
Upside: +257.14%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $2.79
Upside: +724.37%
Aclaris Therapeutics
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.14
Upside: +1,742.11%
Terns Pharmaceuticals
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $6.72
Upside: +108.33%
Gritstone bio
Aug 22, 2022
Downgrades: Sell
Price Target: $2
Current: $0.57
Upside: +249.04%
Radius Health
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $14.67
Upside: -45.47%
Athira Pharma
Dec 15, 2021
Initiates: Neutral
Price Target: n/a
Current: $2.52
Upside: -